]>
IRCT20230526058298N1 IRCT 2023-06-23 Postgraduate Medical Institute Lahore Comparison of Efficacy of Aripiprazole versus Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment of Resistant Obsessive Compulsive Disorder: A Randomized Controlled Trial Comparison of Efficacy of Aripiprazole versus Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment of Resistant Obsessive Compulsive Disorder: A Randomized Controlled Trial 2023-07-01 anticipated 44 Complete https://irct.ir/trial/70836 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization process will be performed by an principal researcher who is directly involved in the study. The randomization sequence will be generated using a random number generator, and participants will be assigned to their respective groups based on the order of enrollment. The allocation sequence will be concealed from the patients, ensuring that they remain blinded to the upcoming assignments, Blinding description: The allocation sequence will be concealed from the patients, ensuring that they remain blinded to the upcoming assignments. the participants involved in the study will not be aware of their group assignment or the specific treatment they are receiving. However, the investigators and research staff will be aware of the group assignments. 1 Obsessive Compulsive Disorder. Intervention 1: In group A: Aripiprazole started with a 2.5 mg daily dose and will be gradually increased to 10 mg daily by the end of the second week. Treatment will be continued for 12 weeks. Intervention 2: In group B, Risperidone initiated with a 1 mg daily dose and was gradually increased to 2 mg daily by the end of the second week. Treatment will be continued for 12 weeks. Yes - There is a plan to make this available What will be shared: primary outcome only When: results for lifelong To whom: to all Conditions: for reference Where to obtain: email How to obtain: email Comments:
public Irfan Jamil
Ferozpur Road Lahore
Lahore Pakistan 54000 +92 311 3773799 irfanravian51@gmail.com Post graduate Medical Institute Lahore scientific Irfan Jamil
Ferozpur road Lahore
Lahore Pakistan 54000 +92 311 3773799 irfanravian51@gmail.com Postgraduate Medical Institute Lahore Pakistan  Patients of age 16-65 years of either gender  Patients diagnosed with obsessive compulsive disorder (as per operational definition) with Y-BOCS score ≥16. 16 years 65 years Both  Pregnant females  Patient allergic to trial drugs  Patient having an organic cause for their symptoms  Patient with comorbid conditions that aggravate the condition or develop depression and anxiety F42 Obsessive-compulsive disorder Treatment - Drugs Treatment - Drugs In group A: Aripiprazole started with a 2.5 mg daily dose and will be gradually increased to 10 mg daily by the end of the second week. Treatment will be continued for 12 weeks. In group B, Risperidone initiated with a 1 mg daily dose and was gradually increased to 2 mg daily by the end of the second week. Treatment will be continued for 12 weeks. YALE-BROWN OBSESSIVE COMPULSIVE SCALE. Timepoint: 3 months. Method of measurement: scoring system. Postgraduate Medical Institute Lahore Approved 2021-09-21 AMC/PGMI/LAHORE GENERAL HOSPITAL Ferozpur road lahore LAHORE PUNJAB Pakistan